50 A recent meta-analysis including thirteen RCTs has shown that semaglutide and tirzepatide treatment significantly increases GI side effects such as nausea, vomiting, diarrhea, and constipation in obese individuals without diabetes compared to control groups
12, Acta Pharmaceutica Sinica B
If you have irregular cycles, severe dysmenorrhea, or hormonal imbalances, your provider should monitor GLP-1 tolerability more closely during your period
If youve struggled with obesity or weight-related conditions, we offer a medical weight loss program designed to support your goals through personalized care, supervised treatments, and effective medications
Notably, Akkermansia muciniphila , often linked to improved insulin sensitivity and reduced inflammation, has shown increased abundance following semaglutide administration, supporting its potential therapeutic relevance [83]
Brand-name Rybelsus uses a proprietary absorption enhancer (SNAC) to improve bioavailability